ACE and diabetic kidney disease: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been documented to delay the progression of DKD by preventing generation of albuminuria, reducing microalbuminuria level, and slowing deterioration of renal function [8,9].